Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma
| Autor: | Sarah N Khan, Edward Lee |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Surgical resection
Yttrium-90 medicine.medical_specialty Carcinoma Hepatocellular Hepatocellular carcinoma Selective internal radiation therapy Review Transarterial chemoembolization 03 medical and health sciences 0302 clinical medicine Transarterial embolization Advanced disease Humans Medicine Yttrium Radioisotopes Chemoembolization Therapeutic Radioembolization lcsh:RC799-869 Surgical treatment Molecular Biology Therapeutic embolization Hepatology business.industry Panitumumab Carcinoma Liver Neoplasms Hepatocellular medicine.disease Bland embolization 030220 oncology & carcinogenesis Bland Embolization Chemoembolization lcsh:Diseases of the digestive system. Gastroenterology 030211 gastroenterology & hepatology Radiology Therapeutic Radiopharmaceuticals business |
| Zdroj: | Clinical and Molecular Hepatology, Vol 23, Iss 4, Pp 265-272 (2017) Clinical and Molecular Hepatology Clinical and molecular hepatology, vol 23, iss 4 |
| ISSN: | 2287-285X 2287-2728 |
| DOI: | 10.3350/cmh.2017.0111 |
| Popis: | Management of hepatocellular carcinoma (HCC) can be maximized with the utilization of multiple treatment modalities including transplant, surgical resection and locoregional therapies including ablative therapies and transarterial embolotherapies. Although transplant and surgical resection offer the best clinical outcomes, a limited number of patients are amenable to these surgical treatment options due to the advanced disease at presentation. Transarterial embolotherapies including conventional transarterial chemoembolization (cTACE), bland transarterial embolization (TAE), drug-eluting beads transarterial chemoembolization (DEB-TACE) and selective internal radiation therapy (SIRT) with Yttrium 90 (90Y) have played an increasingly important role for these patients with unresectable HCC. With a better understanding of different transarterial embolotherapies, more personalized and precise treatment should be implemented for these patients with unresectable HCC. In this review, the updated evidence on the current role of each embolotherapy in the treatment of HCC is summarized. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|